Pfizer's CEO was among the more than 200 pharmaceutical company executives who signed the letter after a federal judge's controversial ruling on mifepristone.
Albert Bourla was among the more than 200 pharmaceutical company executives who signed the letter after U.S. Judge Matthew Kacsmaryk's controversial ruling on Friday.
"If courts can overturn drug approvals without regard for science or evidence, or for the complexity required to fully vet the safety and efficacy of new drugs, any medicine is at risk for the same outcome as mifepristone," the executives said in the letter.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Hayward: Man dies in electric scooter collisionThe incident occurred on the 200 block of Benmore Drive.
Consulte Mais informação »
Ptolemy's hidden Greek text deciphered after 200 yearsAfter 200 years, a hidden Ptolemy text printed beneath a Latin copy has been deciphered.
Consulte Mais informação »
Abortion pill manufacturer Danco Laboratories slams Texas judge's ruling halting FDA approval of mifepristoneDrug manufacturer Danco Laboratories slammed a decision by a Texas judge to halt FDA approval of their abortion pill Mifeprex (mifepristone), vowing to appeal the decision.
Consulte Mais informação »
Federal judge in Texas suspends FDA approval of abortion pillThe ruling from U.S. District Judge Matthew Kacsmaryk in Amarillo could potentially upend access to medication abortion nationwide. Texas mifepristone MedicationAbortion AbortionIsHealthcare abortionrights
Consulte Mais informação »
Federal judge in Texas suspends FDA approval of abortion pillOn Friday, a Texas federal judge ruled to suspend the approval of the abortion-inducing drug mifepristone. The ruling could upend access to medication abortion nationwide. A federal judge in Washington issued a conflicting ruling almost simultaneously.
Consulte Mais informação »